Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
High uncertainty: The valuation methods show significant disagreement (>100% spread). Treat the range as a rough guide rather than a precise estimate.
Bear Case (25th pct.)
-93.5% vs price
Base Case (Median)
-88.2% vs price
Bull Case (75th pct.)
-76.3% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| EV/EBITDA | $34.17 | -88.2% | Medium (20%) |
| EV/FCF | $103.42 | -64.4% | Medium (20%) |
| Earnings Power Value | $3.48 | -98.8% | Medium (50%) |
Based on 3 out of 7 methods, CRL appears overvalued at the current price of $290.19. The base case fair value of $34.17 implies 88.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.